NYSE:RDY Shareholders Notice: Investigation over Possible Securities Laws Violations by Dr. Reddy's Laboratories Limited

An investigation for investors in Dr. Reddy’s Laboratories Limited (NYSE: RDY) shares over potential securities laws violations by Dr. Reddy’s Laboratories was announced.

Logo

San Diego, CA -- (SBWire) -- 08/10/2018 --An investigation was announced on behalf of investors of Dr. Reddy's Laboratories Limited (NYSE: RDY) shares over potential securities laws violations by Dr. Reddy's Laboratories

Investors who purchased shares of Dr. Reddy's Laboratories Limited (NYSE: RDY), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Dr. Reddy's Laboratories Limited (NYSE: RDY) concerning whether a series of statements by Dr. Reddy's Laboratories regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On June 15, 2018, the U.S. District Court for the District of New Jersey granted a request by Indivior PLC ("Indivior") for a temporary restraining order compelling Dr. Reddy's Laboratories Limited's to cease its launch activities related to the Company's Suboxone Film product, pending resolution of Indivior's motion for a preliminary injunction to block the product's release.

On July 13, 2018, the court granted Indivior's motion and entered a preliminary injunction order to that effect.

Those who purchased shares of Dr. Reddy's Laboratories Limited (NYSE: RDY) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

Media Relations Contact

Michael Daniels
General Manager
Shareholders Foundation
858-779-1554
http://www.ShareholdersFoundation.com

View this press release online at: http://rwire.com/1026889